Browse CXCL3

Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Ligand for CXCR2 (By similarity). Has chemotactic activity for neutrophils. May play a role in inflammation and exert its effects on endothelial cells in an autocrine fashion. In vitro, the processed form GRO-gamma(5-73) shows a fivefold higher chemotactic activity for neutrophilic granulocytes.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0040017 positive regulation of locomotion
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0071621 granulocyte chemotaxis
GO:0071622 regulation of granulocyte chemotaxis
GO:0071624 positive regulation of granulocyte chemotaxis
GO:0090022 regulation of neutrophil chemotaxis
GO:0090023 positive regulation of neutrophil chemotaxis
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1902622 regulation of neutrophil migration
GO:1902624 positive regulation of neutrophil migration
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Resistant to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2520.51
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7820.249
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1430.792
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0070.206
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.7180.124
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0790.965
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1530.829
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4490.657
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9760.37
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.5410.434
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9540.29
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1440.627
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL3
Namechemokine (C-X-C motif) ligand 3
Aliases SCYB3; GROg; MIP-2b; CINC-2b; GRO3; GRO3 oncogene; MIP2B; GRO-gamma; GRO-gamma(1-73); MGSA gamma; MIP2-beta; ......
Chromosomal Location4q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.